Journal
FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.560381
Keywords
COVID-19; monocyte; sCD14; sCD163; immunopathology
Categories
Funding
- Instituto de Salud Carlos III: project GePEM (Instituto de Salud Carlos III(ISCIII)/Cofinanciado FEDER) [PI16/01478]
- DIAVIR (Instituto de Salud Carlos III(ISCIII)/FEDER
- Proyecto de Desarrollo Tecnologico en Salud) [DTS19/00049]
- Resvi-Omics (Instituto de Salud Carlos III(ISCIII)/FEDER) [PI19/01039]
- project BIBACVIR (Agencia de Conocimiento en Salud (ACIS)-Servicio Gallego de Salud (SERGAS)-Xunta de Galicia
- Spain) [PRIS-3]
- project ReSVinext (Instituto de Salud Carlos III(ISCIII)/FEDER) [PI16/01569]
- project Enterogen (Instituto de Salud Carlos III(ISCIII)/FEDER)
Ask authors/readers for more resources
Background Emerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind. Methods Fifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group. Results sCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not. Conclusions Monocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available